David A. Siegel 180 Life Sciences Corp. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.12 - $1.31 $720 - $7,860	-6,000 Reduced 32.09%	12,700 $8,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $2.53 $22,194 - $69,322	-27,400 Reduced 59.44%	18,700 $16,000
Q1 2022 May 16, 2022	SELL	$2.53 - $3.9 $8,602 - $13,260	-3,400 Reduced 6.87%	46,100 $119,000
Q4 2021 Feb 14, 2022	BUY	$3.27 - $6.38 $11,772 - $22,968	3,600 Added 7.84%	49,500 $193,000
Q3 2021 Nov 15, 2021	BUY	$5.11 - $10.81 $62,853 - $132,963	12,300 Added 36.61%	45,900 $248,000
Q2 2021 Aug 16, 2021	BUY	$6.7 - $11.98 $225,120 - $402,528	33,600 New	33,600 $336,000

Ticker ATNF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,698,900
Market Cap $88.6M
Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on f...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.